Innovation Never Stops, Achievements Abound: Portfolio Companies Deliver 'Hardcore' Results

Recently, the companies invested in by Yuanhe Holdings' various investment teams have been reporting good news frequently, continuously unleashing innovative momentum and demonstrating strong development potential. Let's take a look at the latest updates from these companies.

SANEGENEBIO's self-developed small nucleic acid (siRNA) drug targeting CFB, SGB-3383 Injection, has recently received the tacit approval for clinical trial application from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) (Acceptance No.: CXHL2500238). It is intended for the treatment of complement-mediated kidney diseases (including IgA nephropathy, C3 glomerulopathy, immune complex-mediated membranoproliferative glomerulonephritis, atypical hemolytic uremic syndrome, etc.).

Innovent Bio's Globally First-in-Class CEACAM5-Targeted Dual-Payload ADC Drug (Research Code: IBI3020) Completes First Dosing in Subjects, Officially Entering Clinical Trial Stage. This is not only the first dual-payload ADC drug produced by Innovent Bio's self-developed ADC platform DuetTx®, but also the world’s first known dual-payload ADC of its kind to complete clinical patient dosing, marking Innovent Bio's innovative strength and breakthrough in ADC technology.

XsellSmart's independently developed "First-in-Class (FIC)" allogeneic "off-the-shelf" iPSC-derived subtype neural cell new drug (XS228 Injection) has officially received a one-time, no-deficiency, full approval from China’s National Medical Products Administration (NMPA) for Phase I and Phase II clinical trial applications. The drug is intended to treat Amyotrophic Lateral Sclerosis (ALS), one of the "five major incurable diseases worldwide." This marks the second universal iPSC-derived cell new drug independently developed by XsellSmart to have dual filings and approvals in both China and the United States for registration clinical trials.

Yak Chemical Headquarters Building Relocation Ceremony Held. The project's total investment exceeds 300 million yuan, mainly used for the research and development, operation, and sales of innovative drugs, generic drugs, biologics, in vitro diagnostic reagents, and new functional materials. It will be developed into an innovation headquarters for synthetic biology and synthetic chemistry.

VINNO Global Headquarters Relocation Launch Ceremony Held. The newly operational global headquarters, with a total investment exceeding 300 million yuan, includes a headquarters building, research and development center, and production base, providing strong support for VINNO's accelerated global expansion. Integrating R&D innovation, intelligent manufacturing, and global operations, the project will serve as a high-end color ultrasound equipment production and R&D base. Upon reaching full production capacity, it is estimated to produce over 20,000 ultrasound devices annually, with an annual output value exceeding 1 billion yuan, further empowering the development of China’s high-end medical device industry.

The main structure of Zhilv Technology's headquarters building project has been topped out, marking the official entry of the project into a new construction phase. As a national high-tech enterprise that researches, produces, and sells core components for new energy vehicles, Zhilv Technology will take this topping-out as the starting point of a new journey. In future interior design, more elements of corporate culture and local culture will be integrated to tell the story of this land, aiming to build the project into a benchmark intelligent manufacturing green factory in the park.

At the 15th anniversary new product launch event of Xiaomi, Xiaomi's first SUV model – Xiaomi YU7 – was officially released. The vehicle innovatively features the 2200MPa Xiaomi Ultra High Strength Steel jointly developed by Xiaomi Auto, Academician Wang Guodong’s team, Yucai Hall, and Northeastern University. It is currently the strongest automotive steel, with a 40% increase in tensile strength compared to 1500MPa hot-formed steel, a 25% improvement in A-pillar load-bearing capacity, and a 70.5% increase in B-pillar load-bearing capacity, achieving a revolutionary breakthrough.

Back to List